|
Age of patient at inclusion
|
17
|
For the increase of one year
|
1.16
|
1.01–1.33
|
0.0403
|
1.19
|
0.98–1.45
|
0.0854
|
|
Severity of FD
|
17
|
1 - Severe vs 0 - Non severe
|
1.17
|
0.12–10.99
|
0.8927
| | | |
|
Kidney failure
|
17
|
1 - Yes vs 0 - No
|
1.33
|
0.19–9.31
|
0.7717
| | | |
|
Hypertrophic cardiomyopathy
|
17
|
1 - Yes vs 0 - No
|
0.48
|
0.07–3.35
|
0.4592
| | | |
|
Duration of replacement treatment
|
17
|
For the increase of 1 year
|
1.26
|
0.96–1.65
|
0.0965
|
1.28
|
0.93–1.74
|
0.1263
|
|
Professional or domestic exposure
|
17
|
1 - Yes vs 0 - No
|
0.87
|
0.05–16.74
|
0.9292
| | | |
|
Tobacco consumption
|
17
|
1 - Yes vs 0 - No
|
0.48
|
0.06–3.99
|
0.4939
| | | |
|
Alcohol consumption
|
17
|
1 - Yes vs 0 - No
|
0.30
|
0.04–2.2
|
0.2363
| | | |
|
Duration of FD from first symptoms
|
16
|
For the increase of 1 year
|
1.05
|
0.96–1.16
|
0.2866
| | | |
|
Age of patient at the beginning of replacement therapy
|
17
|
For the increase of 1 year
|
1.09
|
0.98–1.22
|
0.1222
| | | |
|
Active compound
|
17
|
1 - α-galactosidase vs 2 - ß-galactosidase
|
2.00
|
0.28–14.2
|
0.4882
|
3.77
|
0.21–66.8
|
0.3662
|
